Scinai Immunotherapeutics Ltd (SCNI)vsVertex Pharmaceuticals Inc (VRTX)
SCNI
Scinai Immunotherapeutics Ltd
$0.67
-0.96%
HEALTHCARE · Cap: $2.17M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 1046221% more annual revenue ($12.00B vs $1.15M). VRTX leads profitability with a 32.9% profit margin vs 4.5%. SCNI trades at a lower P/E of 0.2x. VRTX earns a higher WallStSmart Score of 66/100 (B-).
SCNI
Buy61
out of 100
Grade: C+
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+99.6%
Fair Value
$187.20
Current Price
$0.67
$186.53 discount
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Revenue surging 36.1% year-over-year
Earnings expanding 87.2% YoY
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
4.5% margin — thin
Negative free cash flow — burning cash
Distress zone — elevated risk
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : SCNI
The strongest argument for SCNI centers on P/E Ratio, Price/Book, Revenue Growth. Revenue growth of 36.1% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : SCNI
The primary concerns for SCNI are Market Cap, Profit Margin, Free Cash Flow. Thin 4.5% margins leave little buffer for downturns.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
SCNI profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
SCNI carries more volatility with a beta of 1.90 — expect wider price swings.
SCNI is growing revenue faster at 36.1% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 61/100), backed by strong 32.9% margins. SCNI offers better value entry with a 99.6% margin of safety. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Scinai Immunotherapeutics Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Scinai Immunotherapeutics Ltd is an innovative biotechnology firm at the forefront of developing advanced immunotherapy solutions, particularly targeting cancer and autoimmune disorders. Leveraging its proprietary immune modulation platform, Scinai is advancing a promising clinical pipeline designed to deliver transformative therapies that enhance patient outcomes. Guided by a seasoned leadership team with extensive expertise in immunology and drug development, the company is poised to capitalize on the burgeoning demand for groundbreaking immunotherapeutics in the global healthcare market. Scinai's commitment to rigorous research and strategic partnerships further positions it for significant growth and impact within the biopharmaceutical industry.
Visit Website →Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?